Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysi

Jalenques, Isabelle; Bourlot, Fabien; Martínez, Elisa Bermejo; Pereira, Bruno; D’Incan, M.; Lauron, Sophie; Rondepierre, Fabien

doi:10.2340/actadv.v102.1386

Cited by 22 publications

(10 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Moreover, systemic reviews have been separately described in psoriatic patients up to 62% for depressive symptoms and 48% of for anxiety symptoms. 4,5,7,8 The prevalence of both psychological disorders in psoriasis were slightly inconsistent with previous study, which could be explained in each case by methodological and sample factors. Additionally, psoriasis with an adjusted prevalence ratio of 2.698 (95% CI 1.690-4.306) regarding depression and 3.123 (95% CI 1.851-5.269) regarding anxiety compared with general population.…”

contrasting

confidence: 76%

“…Psoriasis is a common, chronic inflammatory psycho-physiological disease, affecting approximately 0.1-11.4% of the general global population and 0.47% of the Chinese. [1][2][3] Recent systemic review indicated the prevalence of comorbid depression up to 62% 4 and anxiety up to 32% 5 in psoriasis, and our previous research also found a high prevalence of depression in psoriasis. 6 Moreover, psychological disorders were proved to be more prevalent in patients with psoriasis than in healthy controls.…”

Section: Introductionmentioning

confidence: 57%

See 1 more Smart Citation

Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study

Tan¹,

Luo²,

Hu³

et al. 2023

CCID

View full text Add to dashboard Cite

Psoriasis patients often suffers from anxiety and depression. Inflammation, anxiety, and depression have been associated with each other, but the relationship has not been examined in subjects with psoriasis. The primary objective was to investigate the relationship between the C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) and depression among patients with psoriasis. Methods: In this case-control, cross-sectional study, 239 individuals with psoriasis and 142 with healthy controls (HCs) were recruited. Psychological as well as clinical, and laboratory data were collected. Results: 50.2% of subjects with psoriasis reported depressive symptoms, compared with 26.8% of HCs. 39.7% and 17.6% observed anxiety symptoms in psoriasis patients and HCs. The odds of anxiety (AOR= 3.123; 95% CI = 1.851-5.269) and depression (AOR= 2.698; 95% CI = 1.690-4.306) were higher in psoriasis patients relative to HCs. Furthermore, the elevated CRP (AOR =2.139; 95% CI = 1.249-3.663) and ESR (AOR =1.827; 95% CI = 1.078-3.096) were the risk factors of depression in patients with psoriasis. The threshold for distinguish psoriasis patients in depression was 3.24 (area under the curve [AUC], 0.605; sensitivity, 0.57; specificity, 0.64) for CRP and 26.5 (AUC, 0.632; sensitivity, 0.52; specificity, 0.73) for ESR. Conclusion: A substantial prevalence of anxiety and depression symptoms was observed in Chinese psoriasis subjects, and the odds were much higher in psoriasis patients relative to HCs. The elevated CRP and ESR level was significantly associated with depression in psoriasis patients. Besides, the discrimination capability of CPR and ESR on depression further indicates the extra value of inflammatory biomarkers in the management of psoriasis patients.

show abstract

contrasting

confidence: 76%

Section: Introductionmentioning

confidence: 57%

Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study

Tan¹,

Luo²,

Hu³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis demonstrated a positive correlation between psoriasis and unspecified anxiety disorder (OR of 1.48 [1.18; 1.85]), as well as between psoriasis and anxiety symptoms (OR of 2.51 [2.02; 3.12]) [ 21 ]. However, as the authors remarked, there is an important heterogeneity between studies, explainable in each instance by methodological factors.…”

Section: Discussionmentioning

confidence: 99%

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients

Beni

Mocan

Florian

et al. 2023

Life

View full text Add to dashboard Cite

Background: Psoriasis is an immune-mediated chronic skin disease that is associated with a significant psychological burden. A newer line of therapy is represented by biologic agents. Our study aimed to evaluate the effect of biologic therapies in the treatment of psoriasis concerning both disease severity and psychological comorbidity. Material and Methods: We performed a prospective case-control comparison to evaluate the prevalence of depression and anxiety in psoriasis patients and unaffected individuals. All patients were recruited between October 2017 and February 2021. Baseline depression (PHQ-9), anxiety (GAD-7), PASI, and DLQI scores were noted. Then, we evaluated the efficacy of biologic treatment in reducing these scores at 6 months of therapy. Patients were treated with either ixekizumab, secukinumab, guselkumab, certolizumab, ustekinumab, risankizumab, or adalimumab. Results: 106 bio-naïve patients with psoriasis and 106 controls without the disease were included in this study. Depression and anxiety were significantly more common among psoriasis patients than in unaffected individuals (p < 0.0001). Female patients presented both depression and anxiety more frequently than men in both case and control groups. Disease severity was significantly associated with worsened depression and anxiety symptoms. Biologic therapy resulted in a significant decrease in all four scores at the 6-month mark for each patient (p < 0.0001). Only an improved PASI correlated significantly with lower depression and anxiety scores (p < 0.005), whereas a decreased DLQI did not (p > 0.955). None of the seven biologic agents used was discovered to be superior. Conclusion: biologic therapies are effective in decreasing both disease severity and alleviating depression and anxiety symptoms in psoriasis.

show abstract

“…Comparison of patients according to the occurrence or not of a psychiatric disorder confirmed that patients who developed a psychiatric disorder had higher psychic anxiety symptom scores at baseline (S3 Table ). Although they had higher scores overall the only significant increases were in the psychic anxiety symptom scores (4 [3-6] vs 1.5 [0-3.5] p = 0.008) and the total HAMA scores (18 [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] ). These patients had also received more past psychotropic treatment (hypnotic) (S3 Table ).…”

Section: Psychiatric Evolution and Associated Baseline Factorsmentioning

confidence: 99%

“…A later study described the chronology of symptom onset in interferon-treated patients, who first developed neurovegetative and somatic symptoms and then anxious and depressive symptoms [ 18 ]. Since then, many studies have looked for links between inflammation and depressive symptoms, including in chronic inflammatory diseases [ 4 , 6 , 8 , 9 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Psychiatric symptomatology in skin-restricted lupus patients without axis I psychiatric disorders: A post-hoc analysis

Rondepierre¹,

Tauveron-Jalenques²,

Valette³

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Skin-restricted lupus is a chronic inflammatory disease associated with high rates of depression and anxiety disorders. Patients without psychiatric disorders can experience anxiety and depressive symptoms at a subclinical level, which could be risk factors for progression towards psychiatric disorders. It was decided, therefore, to investigate the presence of specific symptoms in skin-restricted lupus patients without axis I psychiatric disorders and their impact on the occurrence of axis I psychiatric disorders during the study follow-up. Methods Longitudinal data of 38 patients and 76 matched controls without active axis I psychiatric disorders from the LuPsy cohort were used. Depressive, neurovegetative, psychic and somatic anxiety symptom scores were established from the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating scale (HAMA). Results None of the participants had any current active axis I psychiatric disorders but the patients had personality disorders more frequently and had received more past psychotropic treatments than the controls. They also had higher MADRS and HAMA scores than the controls, in particular neurovegetative, psychic anxiety and somatic symptoms scores. No dermatological factor tested was associated with these scores, whereas being a lupus patient was associated with higher neurovegetative and somatic symptoms scores, having a current personality disorder with higher depressive and neurovegetative scores and receiving more past psychotropic treatments with psychic anxiety and somatic symptoms scores. The occurrence of psychiatric disorders during the study follow-up was associated with an elevated psychic anxiety score at baseline and past psychotropic treatment but not with history of psychiatric disorder. Limitations The LuPsy cohort included a large number of patients with axis I psychiatric disorders, the sample without axis I psychiatric disorders is therefore limited. Conclusions We observed numerous psychiatric symptoms among the skin-restricted lupus patients. They should therefore receive special attention in the management of their subclinical symptoms before they progress towards full psychiatric disorders.

show abstract

Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysi

Cited by 22 publications

References 120 publications

Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study

Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients

Psychiatric symptomatology in skin-restricted lupus patients without axis I psychiatric disorders: A post-hoc analysis

Contact Info

Product

Resources

About